CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite
Table 1 from Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. | Semantic Scholar
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - ScienceDirect
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Comparison of the performance of total CA 19-9 and the marker panel in... | Download Table
Comparison between CEA, CA 19-9 and CA 72-4 in Patients with Colon Cancer
Tumor marker CA 19.9 and CEA studies, with TNM staging at presentation | Download Scientific Diagram
Tumour marker CA 19-9 - Pancreatic Cancer - little known - little heeded
Cancer marker CA 19-9 (pancreatic) - Telesante
CA19-9 for detecting recurrence of pancreatic cancer | Scientific Reports
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Tumor Marker CA 19-9 for Assessing Pancreatic Cancer Response - Cancer Therapy Advisor
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma | PLOS ONE
Tumour marker CA 19-9 - Pancreatic Cancer - little known - little heeded
Tumor marker CA 19.9 and CEA studies, with TNM staging at presentation | Download Scientific Diagram
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text
Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers
Cancer marker CA 19-9 (pancreatic) - Telesante
Table 1 from Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar
Tumor Marker Control | Fujirebio
Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening | Scientific Reports
![PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f7bb4eb6de25f6ecb9323cbef8061896f020a0da/2-Table1-1.png "PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar")
PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar
